血糖对急性缺血性卒中静脉溶栓治疗后结局的影响

doi:10.3969/j.issn.1006-7795.2017.01.011

摘要/Abstract

摘要： 目的探讨血糖指标对急性缺血性卒中静脉溶栓治疗后结局的影响。方法纳入202例接受静脉溶栓治疗的缺血性卒中病例分析。终点事件包括疗效指标（如出院时良好预后定义为改良Rankin评分≤2，早期神经功能改善，早期神经功能恶化和血管再通）和安全性指标（症状性脑出血和全部脑出血）。结果所纳入病例的中位年龄为61岁，其中25.2%为女性，美国国立卫生研究院卒中量表（National Institute of Health Stoke Scale，NIHSS）的中位评分为9分，中位发病至静脉溶栓给药（onset to needle，OTN）时间为230 min。血糖指标中，良好预后组和有血管再通组的中位空腹血糖显著升高，但在全部脑出血及症状性脑出血的组间比较，差异无统计学意义（P>0.05）；空腹血糖在有症状性脑出血亚组显著升高，在其他组间比较，差异无统计学意义（P>0.05）。糖化血红蛋白在所有组间比较中差异均无统计学意义（P>0.05）。在校正年龄、性别、发病至静脉溶栓给药时间和NIHSS后，入院基线随机血糖是症状性脑出血的唯一独立影响因素，其比值比（odds ratio，OR）为1.24，对应的95%可信区间（confidence interval，CI）为1.03~1.50；而空腹血糖则与出院时预后良好，早期神经功能改善和血管再通均负性相关，对应的OR及95%CI分别为0.72（0.58~0.90），0.69（0.55~0.87），和0.80（0.66~0.98）。校正混淆因素后，高空腹血糖浓度与非症状性脑出血相关的早期神经功能恶化显著相关，对应的OR及95% CI为1.42（1.04~1.95）。结论缺血性卒中急性期的血糖指标可能是静脉溶栓治疗后结局终点事件的独立影响因素，而空腹血糖升高很可能通过降低静脉溶栓的疗效反应而非增加症状性脑出血不良反应对功能预后产生不利影响。

关键词: 血糖, 缺血性卒中, 阿替普酶, 静脉溶栓, 结局, 安全性

Abstract: Objective To investigate the association between glucose parameters and outcome measures in acute ischemic stroke (AIS) treated with intravenous thrombolysis (IVT). Methods Two hundred and two eligible cases were enrolled in the cohort study. Blood glucose (BG), fasting BG and glycosylated hemoglobin A1c (HbA1c) determined on admission were taken as continuous variables, therapeutic outcome measures[e.g., modified Rankin Scale (mRS)≤2 at discharge, early neurological improvement (ENI) or deterioration (END), and recanalization status] and safety outcome measures[symptomatic intracranial hemorrhage (SICH) and all intracranial hemorrhage (ICH)] were taken as endpoint indicators. Results Of the recruited cases, the median age was 61 years, 25.2% female, median National Institute of Health Stoke Scale (NIHSS) 9 scores and onset to needle (OTN) time 230 min. The median fasting BGs were much lower in subgroups with favorable outcome (mRS≤2) or recanalization than those in the related reference subgroups, while the comparisons according to ICH and SICH didn't reach significance. Significantly higher admission BG was only found in the comparison according to SICH and the HbA1c levels were similar in all comparisons. Adjusted for age, sex, OTN and baseline NIHSS, admission BG[odds ratio (OR), 1.24; 95% confidence interval (CI):1.03-1.50] was the only independent predictor of SICH, while fasting BG was negatively associated with all therapeutic outcome measures, with an OR of 0.72 (0.58-0.90) for mRS≤2 at discharge, an OR of 0.69 (0.55-0.87) for ENI, and an OR of 0.80 (0.66-0.98) for recanalization. Elevated fasting BG was only significantly associated with Non-SICH related END (OR:1.42, 95%CI:1.04-1.95) after adjustment for explanatory variables.Conclusion Acute glucose parameters could be independent predictors of outcomes in AIS after IVT and elevated fasting BG negatively affected the functional outcome probably through the mechanism of an impaired response of IVT.

Key words: blood glucose, ischemic stroke, alteplase, intravenous thrombolysis, outcome, safety

中图分类号:

R743.3

黄镪, 马青峰, 宋海庆, 武剑. 血糖对急性缺血性卒中静脉溶栓治疗后结局的影响[J]. 首都医科大学学报, 2017, 38(1): 53-58.

Huang Qiang, Ma Qingfeng, Song Haiqing, Wu Jian. Association between glucose parameters and outcome measures in acute ischemic stroke with intravenous thrombolytic treatment[J]. Journal of Capital Medical University, 2017, 38(1): 53-58.

参考文献

[1] Uyttenboogaart M, Koch M W, Stewart R E, et al. Moderate hyperglycaemia is associated with favourable outcome in acute lacunar stroke[J]. Brain, 2007,130(Pt 6):1626-1630.
[2] Desilles J P, Meseguer E, Labreuche J, et al. Diabetes mellitus, admission glucose, and outcomes after stroke thrombolysis:a registry and systematic review[J]. Stroke, 2013,44(7):1915-1923.
[3] Walters M R, Weir C J, Lees K R. A randomised, controlled pilot study to investigate the potential benefit of intervention with insulin in hyperglycaemic acute ischaemic stroke patients[J]. Cerebrovasc Dis, 2006,22(2-3):116-122.
[4] Gray C S, Hildreth A J, Sandercock P A, et al. Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia:the UK Glucose Insulin in Stroke Trial (GIST-UK)[J]. Lancet Neurol, 2007,6(5):397-406.
[5] Johnston K C, Hall C E, Kissela B M, et al. Glucose Regulation in Acute Stroke Patients (GRASP) trial:a randomized pilot trial[J]. Stroke, 2009,40(12):3804-3809.
[6] McCormick M, Hadley D, McLean J R, et al. Randomized, controlled trial of insulin for acute poststroke hyperglycemia[J]. Ann Neurol, 2010,67(5):570-578.
[7] Piironen K, Putaala J, Rosso C, et al. Glucose and acute stroke:evidence for an interlude[J]. Stroke, 2012,43(3):898-902.
[8] Yoo D S, Chang J, Kim J T, et al. Various blood glucose parameters that indicate hyperglycemia after intravenous thrombolysis in acute ischemic stroke could predict worse outcome[J]. PLoS One, 2014,9(4):e94364.
[9] Hu G C, Hsieh S F, Chen Y M, et al. The prognostic roles of initial glucose level and functional outcomes in patients with ischemic stroke:difference between diabetic and nondiabetic patients[J]. Disabil Rehabil, 2012,34(1):34-39.
[10] 中华医学会神经病学分会脑血管病学组急性缺血性脑卒中诊治指南撰写组. 中国急性缺血性脑卒中诊治指南2010[J]. 中华神经科杂志, 2010,14(2):4013-4017.
[11] Adams H J, Del Z G, Alberts M J, et al. Guidelines for the early management of adults with ischemic stroke:a guideline from the american heart association/american stroke association stroke council, clinical cardiology council, cardiovascular radiology and intervention council, and the atherosclerotic peripheral vascular disease and quality of care outcomes in research interdisciplinary working groups:the american academy of neurology affirms the value of this guideline as an educational tool for neurologists[J]. Stroke, 2007,38(5):1655-1711.
[12] Little R R, Rohlfing C L, Wiedmeyer H M, et al. The national glycohemoglobin standardization program:a five-year progress report[J]. Clin Chem, 2001,47(11):1985-1992.
[13] 华扬, 高山, 吴钢, 等. 经颅多普勒超声操作规范及诊断标准指南[J]. 中华医学超声杂志:电子版, 2008,5(2):197-222.
[14] Nagaraja N, Warach S, Hsia A W, et al. Association between neurologic improvement with decline in blood pressure and recanalization in stroke[J]. JAMA Neurol, 2014,71(12):1555-1558.
[15] Zinkstok S M, Beenen L F, Majoie C B, et al. Early deterioration after thrombolysis plus aspirin in acute stroke:a post hoc analysis of the Antiplatelet Therapy in Combination with Recombinant t-PA Thrombolysis in Ischemic Stroke trial[J]. Stroke, 2014,45(10):3080-3082.
[16] 黄镪, 武剑. 静脉溶栓后出血转化的风险预测的研究进展[J]. 中国卒中杂志, 2013,8(3):190-194.
[17] Cucchiara B, Kasner S E, Tanne D, et al. Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke:pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II Trials[J]. Stroke, 2009,40(9):3067-3072.
[18] Strbian D, Meretoja A, Ahlhelm F J, et al. Predicting outcome of IV thrombolysis-treated ischemic stroke patients:the DRAGON score[J]. Neurology, 2012,78(6):427-432.
[19] Kerr D M, Fulton R L, Higgins P, et al. Response of blood pressure and blood glucose to treatment with recombinant tissue-type plasminogen activator in acute ischemic stroke:evidence from the virtual international stroke trials archive[J]. Stroke, 2012,43(2):399-404.
[20] Luitse M J, Biessels G J, Rutten G E, et al. Diabetes, hyperglycaemia, and acute ischaemic stroke[J]. Lancet Neurol, 2012,11(3):261-271.
[21] Vaidyula V R, Rao A K, Mozzoli M, et al. Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand[J]. Diabetes, 2006,55(1):202-208.
[22] Ribo M, Molina C, Montaner J, et al. Acute hyperglycemia state is associated with lower tPA-induced recanalization rates in stroke patients[J]. Stroke, 2005,36(8):1705-1709.
[23] Fan X, Ning M, Lo E H, et al. Early insulin glycemic control combined with tPA thrombolysis reduces acute brain tissue damages in a focal embolic stroke model of diabetic rats[J]. Stroke, 2013,44(1):255-259.